Interestingly, the competitive advantage of TLR-TRAF6-primed HSPCs could be restored by deletion of A20 or inhibition of the noncanonical NF-κB pathway, therefore suggesting that interfering with noncanonical NF-κB signaling could prevent MDS progression [59]. This evidence concerns the gene TRAF6 and myelodysplastic syndrome.